1. < MAC & Bronchiectasis

Good news, Bensocatib Trials Continue for Bronchieactasis

Posted by harrynsc @harrynsc, May 28 5:32pm

For non-cystic fibrosis bronchiectasis
New drug; new mechanism
Insmed company

https://www.investors.com/news/technology/insmed-stock-non-cystic-fibrosis-bronchiectasis-brensocatib/?src=A00220

Interested in more discussions like this? Go to the MAC & Bronchiectasis Support Group.

becleartoday | @becleartoday | May 28 3:43pm

Brensocatib--
Insmed said its experimental drug to treat a type of chronic lung disease helped significantly reduce respiratory symptoms such as chronic cough in a late-stage study.
The drug candidate, brensocatib, is being developed to treat patients with non-cystic fibrosis bronchiectasis, a chronic lung condition where the walls of the airways are widened due to inflammation and infection.
The company said it plans to file a marketing application for brensocatib with the U.S. Food and Drug Administration in the fourth quarter of this year, and it expects to launch the drug in mid-2025.

REPLY
4 replies
scoop | @scoop | May 28 4:12pm
In reply to @becleartoday "Brensocatib-- Insmed said its experimental drug to treat a type of chronic lung disease helped significantly..." + (show)
@becleartoday

Brensocatib--
Insmed said its experimental drug to treat a type of chronic lung disease helped significantly reduce respiratory symptoms such as chronic cough in a late-stage study.
The drug candidate, brensocatib, is being developed to treat patients with non-cystic fibrosis bronchiectasis, a chronic lung condition where the walls of the airways are widened due to inflammation and infection.
The company said it plans to file a marketing application for brensocatib with the U.S. Food and Drug Administration in the fourth quarter of this year, and it expects to launch the drug in mid-2025.

Jump to this post

Thanks for posting! Curious how you read this? Does "late stage" seem less than what they set out to do?

REPLY
1 reply
becleartoday | @becleartoday | May 28 4:28pm
In reply to @scoop "Thanks for posting! Curious how you read this? Does "late stage" seem less than what they..." + (show)
@scoop

Thanks for posting! Curious how you read this? Does "late stage" seem less than what they set out to do?

Jump to this post

Hi Scoop! They are on target with the study and excited about the topline results!

REPLY
liz440 | @liz440 | May 28 5:59pm

This is very interesting. The lower dose was more effective. Should take maybe 6-10 months for FDA approval...then wait a bit and see if there is any bad consequence of the drug.

REPLY
scoop | @scoop | May 28 6:12pm

"Side effects included Covid, inflammation of the nasal passages, cough and headache."

We will have to see!

REPLY
2 replies
liz440 | @liz440 | May 28 6:23pm

you can't get covid out of the blue. you have to have been exposed. Maybe they mean you are more "susceptible" to covid but then why not other viruses?

REPLY
narelled23 | @narelled23 | May 28 10:31pm
In reply to @scoop ""Side effects included Covid, inflammation of the nasal passages, cough and headache." We will have to..." + (show)
@scoop

"Side effects included Covid, inflammation of the nasal passages, cough and headache."

We will have to see!

Jump to this post

Yes.. very interesting side effects!

REPLY
Rick | @rstel7272 | May 29 7:12am
In reply to @scoop ""Side effects included Covid, inflammation of the nasal passages, cough and headache." We will have to..." + (show)
@scoop

"Side effects included Covid, inflammation of the nasal passages, cough and headache."

We will have to see!

Jump to this post

Already had those 4 side effects the last 6 months and a few others to boot 🙁

REPLY
fdixon63 | @fdixon63 | May 29 7:44am
In reply to @becleartoday "Brensocatib-- Insmed said its experimental drug to treat a type of chronic lung disease helped significantly..." + (show)
@becleartoday

Brensocatib--
Insmed said its experimental drug to treat a type of chronic lung disease helped significantly reduce respiratory symptoms such as chronic cough in a late-stage study.
The drug candidate, brensocatib, is being developed to treat patients with non-cystic fibrosis bronchiectasis, a chronic lung condition where the walls of the airways are widened due to inflammation and infection.
The company said it plans to file a marketing application for brensocatib with the U.S. Food and Drug Administration in the fourth quarter of this year, and it expects to launch the drug in mid-2025.

Jump to this post

Hi becleartoday. OK, my need for clarification is, what is topline results? Thanks.

REPLY
becleartoday | @becleartoday | May 29 7:49am
In reply to @becleartoday "Brensocatib-- Insmed said its experimental drug to treat a type of chronic lung disease helped significantly..." + (show)
@becleartoday

Brensocatib--
Insmed said its experimental drug to treat a type of chronic lung disease helped significantly reduce respiratory symptoms such as chronic cough in a late-stage study.
The drug candidate, brensocatib, is being developed to treat patients with non-cystic fibrosis bronchiectasis, a chronic lung condition where the walls of the airways are widened due to inflammation and infection.
The company said it plans to file a marketing application for brensocatib with the U.S. Food and Drug Administration in the fourth quarter of this year, and it expects to launch the drug in mid-2025.

Jump to this post

Topline results in a clinical trial refer to the high-level summary of the key findings from the trial. They typically include the primary efficacy and safety data points, without providing the full detailed results or analysis.

REPLY
View MoreView Less
Please sign in or register to post a reply.